2024-515744-23-00已完成1 期
A trial in patients with blood cancer and lymphatic system cancer looking at finding the optimal dose of BMF-219
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 14
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Biomea Fusion, Inc. Clinical Operations
Scientific
Biomea Fusion Inc.
研究点 (14)
Loading locations...
相似试验
招募中
2 期
A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible patients2024-517321-99-00HUS-Yhtymae120
招募中
2 期
Phase II study of (early) combination salvage therapy with Venetoclax and intensified Decitabine in Relapsed/Refractory AML2022-502665-15-00Universitaetsklinikum Tuebingen27
招募中
2 期
Evaluation of the efficacy and safety of Rituximab in patients with Amyotrophic Lateral Sclerosis (ALS)2022-502743-35-00Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.52
招募中
1 期
Oncolytic virus TILT-123 in combination with lymphocyte-depleting chemotherapy and TILs in the treatment of melanomaMelanoma2024-514092-18-00TILT Biotherapeutics Oy9
招募中
3 期
A phase III trial of a De-escalated Immune-strategy During first-line treAtment in patients with metastatic non-small Cell lung cancer (NSCLC): DIDaC2025-520792-67-00Leids Universitair Medisch Centrum (LUMC)500